Ondine Biomedical Inc. (AIM:OBI)

Ondine Biomedical Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2.05	1.2	0.64	2.57	1.79
Revenue Growth (YoY)	70.32%	88.56%	-75.17%	43.44%	16.84%
Cost of Revenue	0.73	0.5	0.35	1.32	1.14
Gross Profit	1.32	0.7	0.29	1.25	0.65
Selling, General & Admin	11.01	9.8	12.31	13.33	12.04
Research & Development	9.22	5.14	6.28	4.98	3.31
Operating Expenses	20.77	15.51	19.05	18.77	16.52
Operating Income	-19.44	-14.81	-18.76	-17.52	-15.87
Interest Expense	-0.03	-0.05	-0.03	-0.01	-0.49
Interest & Investment Income	0.03	0.24	0.19	-	-
Currency Exchange Gain (Loss)	0.04	-0.14	0.64	0.19	0.14
Other Non Operating Income (Expenses)	0.3	0	-1.33	-1.63	-0.05
EBT Excluding Unusual Items	-19.1	-14.75	-19.29	-18.98	-16.27
Gain (Loss) on Sale of Assets	-	-0.1	-0.08	-	-
Other Unusual Items	-	0.44	-	-31.11	-
Pretax Income	-19.1	-14.41	-19.37	-50.09	-16.27
Net Income	-19.1	-14.41	-19.37	-50.09	-16.27
Net Income to Common	-19.1	-14.41	-19.37	-50.09	-16.27
Shares Outstanding (Basic)	275	197	195	80	71
Shares Outstanding (Diluted)	275	197	195	80	71
Shares Change (YoY)	39.31%	1.30%	144.34%	12.69%	761.95%
EPS (Basic)	-0.07	-0.07	-0.10	-0.63	-0.23
EPS (Diluted)	-0.07	-0.07	-0.10	-0.63	-0.23
Free Cash Flow	-15.5	-13.83	-16.66	-12.62	-6.36
Free Cash Flow Per Share	-0.06	-0.07	-0.09	-0.16	-0.09
Gross Margin	64.47%	58.44%	44.98%	48.81%	36.24%
Operating Margin	-948.95%	-1230.67%	-2940.91%	-681.98%	-886.15%
Profit Margin	-932.06%	-1198.01%	-3036.36%	-1949.59%	-908.49%
Free Cash Flow Margin	-756.47%	-1149.63%	-2610.66%	-491.13%	-355.00%
EBITDA	-19.24	-14.59	-18.54	-17.24	-14.91
D&A For EBITDA	0.21	0.21	0.22	0.28	0.96
EBIT	-19.44	-14.81	-18.76	-17.52	-15.87
Advertising Expenses	0.13	0.18	0.23	0.14	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.